The Rarity of Adverse Events With Natalizumab Infusion for MS
April 8, 2021 Victoria Johnson NeurologyLive, Advances in Multiple Sclerosis, Yujie Wang, MD, a neurologist from the University of Washington Medical…
Tysabri Affects Immune System Beyond Known MS Target, Study Finds
NOVEMBER 24, 2020 — BY STEVE BRYSON PHD – MS News Today Click HERE to Subscribe for the MS Beacon…
Stuart Schlossman
Natalizumab (Tysabri) Provides Superior ‘Feel Good’ Experience in MS Over Other Treatments
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ COVID-19 is unprecedented and rapidly changing situation. Get public health information from CDC: https://www.coronavirus.gov Stay Healthy, Stay Home and Wash…
Stuart Schlossman
Long-term Safety and Effectiveness of Natalizumab Treatment in Clinical Practice: 10 Years of Real-World Data From the Tysabri Observational Program (TOP)
2020 Mar 31 Helmut Butzkueven 1, Ludwig Kappos 2, Heinz Wiendl 3, Maria Trojano 4, Tim Spelman 5 6, Ih Chang 7, Rachna Kasliwal 8, Seema Jaitly 8, Nolan Campbell 9, Pei-Ran Ho 9, Stephanie Licata 10, Tysabri Observational Program (TOP) Investigators Collaborators,…
Stuart Schlossman
What to Know About MS and the JC Virus
This common virus is harmless to most of the population. But it can have serious effects for those with multiple…
Stuart Schlossman
#ECTRIMS2019 – Tysabri During Pregnancy and After Delivery Seems Safe, Reduces Relapse Risk, Study Finds
Click here to subscribe to the MS Beacon e-Newsletter by MS Views and News Continuing Tysabri (natalizumab) treatment up to week 28…
Stuart Schlossman
Multiple Sclerosis Vlog: Decoding the JC Virus Antibody Test
Aaron Boster MD Published on Jun 2, 2019 In this video I teach you how to understand the JC virus…
Stuart Schlossman
Phase 3 Trial Finds Tysabri Lowers Serum Neurofilament Light Levels in SPMS Patients
MAY 7, 2019 BY JOSE MARQUES LOPES, PHD Treatment with Tysabri (natalizumab) lowers the levels of the biomarker serum neurofilament light chain…
Stuart Schlossman
Decline in Brain Volume Driven by Gray Matter Atrophy in MS Patients Despite Tysabri Treatment
BY JONATHAN GRINSTEIN This finding points to new markers for MS disease progression, and the need to monitor the effectiveness of treatment…
Stuart Schlossman
Tysabri Seen as Superior to IFN-β in Preventing Relapses, Easing Disability in Small Study
DECEMBER 7, 2018 BY ALBERTO MOLANO Tysabri (natalizumab) was found to be superior to interferon beta (IFN-β) in a small, 12-month…
Stuart Schlossman
